Relentlessly fighting a smarter war against GI cancer by partnering with patients based on their unique needs, the Ruesch Center is committed to providing you with the highest standard of care and individualized cures.
Although colorectal cancer is one of the most commonly diagnosed cancers in the United States,1 and researchers’ understanding of the biology and pathophysiology of CRC has grown, its many variations require that each case be diagnosed with care.
In the search to establish new therapeutic options for patients with advanced hepatocellular carcinoma (HCC), immunotherapy has become a frontrunner in many clinical trials in the first-line setting, according to Michael J. Pishvaian, MD, PhD.
Former Vice President Joe Biden was among those who were recognized for improving the lives of patients with gastrointestinal cancer at the Second Annual Luminary Awards, hosted by the Ruesch Center and OncLive.
At a panel discussion on innovation and challenges in clinical research, panelist discussed difficulties related to planning clinical trials for patients with rare tumor types within the existing paradigm.
OncLive® and The Ruesch Center, the founding partners of the Luminary Awards in GI Cancers, congratulate the 2018 honorees recognized at the Second Annual Luminary Awards ceremony, which was held Thursday, Nov. 29 in Washington, D.C.
At the 2nd Annual Luminary Awards, hosted by OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers, several individuals in the cancer care community were honored for their efforts in improving the lives of patients with gastrointestinal cancers.
Dr. Marshall discusses the obstacles to global clinical research and how these may be overcome.
Sign Up to receive all Ruesch updates directly in your Inbox
We will deliver our quarterly newsletter, monthly updates and other announcements to your Inbox with information on upcoming special events, current clinical trials and cutting edge research and trends in the GI cancer field.